
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7577376/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Preoperative echocardiography as a prognostic tool for liver transplant in patients with hypertrophic cardiomyopathy. Clinical Transplantation, 2022, 36, e14538.	0.8	4
2	PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68Gaâ€₽SMAâ€11 PET Using Cyclotronâ€Produced 68Ga. Hepatology Communications, 2022, 6, 1172-1185.	2.0	15
3	Reply. Liver Transplantation, 2022, 28, 732-732.	1.3	2
4	The fundamentals of sexâ€based disparity in liver transplantation: Understanding can lead to change. Liver Transplantation, 2022, 28, 1367-1375.	1.3	6
5	De Novo Malignancy After Liver Transplantation: Risk Assessment, Prevention, and Management—Guidelines From the ILTS-SETH Consensus Conference. Transplantation, 2022, 106, e30-e45.	0.5	29
6	Personalizing Diabetes Management in Liver Transplant Recipients: The New Era for Optimizing Risk Management. Hepatology Communications, 2022, 6, 1250-1261.	2.0	3
7	The ILTS-SETH Consensus Conference on Extrahepatic Cancer and Liver Transplantation: Paving the Way. Transplantation, 2022, 106, e1-e2.	0.5	2
8	DNA methylation profile of liver tissue in end-stage cholestatic liver disease. Epigenomics, 2022, 14, 481-497.	1.0	2
9	Increasing nonalcoholic steatohepatitis overlap in liver transplant recipients: Additive risk for de novo malignancy. Clinical Transplantation, 2022, , e14714.	0.8	0
10	Infectious complications in acute graftâ€versusâ€host disease after liver transplantation. Transplant Infectious Disease, 2022, 24, .	0.7	2
11	Growth hormone deficiency and NAFLD: An overlooked and underrecognized link. Hepatology Communications, 2022, 6, 2227-2237.	2.0	15
12	Greater Muscular Strength Is Associated with a Lower Risk of Pulmonary Dysfunction in Individuals with Non-Alcoholic Fatty Liver Disease. Journal of Clinical Medicine, 2022, 11, 4151.	1.0	1
13	Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis. Clinical Gastroenterology and Hepatology, 2021, 19, 146-154.e4.	2.4	75
14	Circulating Extracellular Vesicles Carrying Sphingolipid Cargo for the Diagnosis and Dynamic Risk Profiling of Alcoholic Hepatitis. Hepatology, 2021, 73, 571-585.	3.6	56
15	Role of symmetric dimethylarginine in predicting future renal impairment in liver transplant recipients. Transplant International, 2021, 34, 207-208.	0.8	0
16	Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 475-483.	2.6	45
17	Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underused Potential. Hepatology, 2021, 73, 2051-2062.	3.6	10
18	Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 460-474.	2.6	67

#	Article	IF	CITATIONS
19	Cirrhotic cardiomyopathy prevalence according to the new criteria. Liver International, 2021, 41, 1170-1170.	1.9	3
20	Liver chemistries in glycogenic hepatopathy associated with type 1 diabetes mellitus: A systematic review and pooled analysis. Liver International, 2021, 41, 1545-1555.	1.9	8
21	Scientific Relief: When Science and Technology Agree and Lead. Liver Transplantation, 2021, 27, 484-485.	1.3	Ο
22	Reply. Liver Transplantation, 2021, 27, 1070-1070.	1.3	0
23	Liver transplantation for acute liver failure in a SARS-CoV-2 PCR-positive patient. American Journal of Transplantation, 2021, 21, 2890-2894.	2.6	23
24	Long-term mortality risk stratification of liver transplant recipients: real-time application of deep learning algorithms on longitudinal data. The Lancet Digital Health, 2021, 3, e295-e305.	5.9	41
25	Liver Transplantation After Bariatric Surgery: a Clinical Cohort Study. Obesity Surgery, 2021, 31, 3700-3706.	1.1	13
26	Cirrhotic Cardiomyopathy Predicts Posttransplant Cardiovascular Disease: Revelations of the New Diagnostic Criteria. Liver Transplantation, 2021, 27, 876-886.	1.3	37
27	De Novo Colorectal and Pancreatic Cancer in Liverâ€Transplant Recipients: Identifying the Higherâ€Risk Populations. Hepatology, 2021, 74, 1003-1013.	3.6	11
28	Physiologic Reserve Assessment and Application in Clinical and Research Settings in Liver Transplantation, 2021, 27, 1041-1053.	1.3	9
29	Efficacy and Safety of Endoscopic Balloon Placement for Weight Loss in Patients With Cirrhosis Awaiting Liver Transplantation. Liver Transplantation, 2021, 27, 1239-1247.	1.3	11
30	Risks and Rewards of Bariatric Surgery in Advanced Chronic Liver Diseases. Seminars in Liver Disease, 2021, 41, 448-460.	1.8	9
31	REPLY:. Hepatology, 2021, 74, 2913-2913.	3.6	0
32	Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria. HemaSphere, 2021, 5, e640.	1.2	7
33	Non-selective beta blockers and mortality in decompensated cirrhosis: Is cirrhotic cardiomyopathy the missing link?. Journal of Hepatology, 2021, 75, 992-993.	1.8	1
34	Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C. Transplantation Direct, 2021, 7, e635.	0.8	4
35	Association of α 1 Antitrypsin Phenotype and Development of Advanced Liver Disease and Pulmonary Complications Before and After Liver Transplantation. Transplantation, 2021, 105, 1576-1584.	0.5	4
36	Bariatric surgery proves long-term benefit in patients with cirrhosis. Gastroenterology Report, 2021, 9, 252-256.	0.6	5

#	Article	IF	CITATIONS
37	Redefining Cirrhotic Cardiomyopathy for the Modern Era. Hepatology, 2020, 71, 334-345.	3.6	195
38	Reply:. Hepatology, 2020, 71, 1884-1885.	3.6	1
39	Applying Machine Learning in Liver Disease and Transplantation: A Comprehensive Review. Hepatology, 2020, 71, 1093-1105.	3.6	110
40	Diabetogenic Effects of Immunosuppression: An Integrative Analysis. Transplantation, 2020, 104, 211-221.	0.5	9
41	Enteric dysbiosis in liver and kidney transplant recipients: a systematic review. Transplant International, 2020, 33, 1163-1176.	0.8	5
42	Ultrasound Attenuation Estimation in Harmonic Imaging for Robust Fatty Liver Detection. Ultrasound in Medicine and Biology, 2020, 46, 3080-3087.	0.7	10
43	Peripheral Endothelial Function as a Marker of Systemic Vasodilation in End-stage Liver Disease: Results of a Pilot Study. Transplantation Direct, 2020, 6, e546.	0.8	Ο
44	Psychosocial Risk Impacts Mortality in Women After Liver Transplantation. Psychosomatics, 2019, 60, 56-65.	2.5	13
45	Management of Recurrent and De Novo NAFLD/NASH After Liver Transplantation. Transplantation, 2019, 103, 57-67.	0.5	64
46	Autoimmune hepatitis: Current and future therapeutic options. Liver International, 2019, 39, 1002-1013.	1.9	36
47	Longâ€ŧerm outcomes of the octogenarian donor liver recipient: The era of the new centurion. Clinical Transplantation, 2019, 33, e13629.	0.8	2
48	Liver Transplantation Trends and Outcomes for Hereditary Hemorrhagic Telangiectasia in the United States. Transplantation, 2019, 103, 1418-1424.	0.5	15
49	Sarcopenia in Cirrhosis: Looking Beyond the Skeletal Muscle Loss to See the Systemic Disease. Hepatology, 2019, 70, 2193-2203.	3.6	58
50	The evolution and impact of sarcopenia pre―and postâ€liver transplantation. Alimentary Pharmacology and Therapeutics, 2019, 49, 807-813.	1.9	55
51	Understanding and managing cardiovascular outcomes in liver transplant recipients. Current Opinion in Organ Transplantation, 2019, 24, 148-155.	0.8	20
52	Women With Nonalcoholic Fatty Liver Disease Lose Protection Against Cardiovascular Disease: A Longitudinal Cohort Study. American Journal of Gastroenterology, 2019, 114, 1764-1771.	0.2	34
53	Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2019, 49, 64-73.	1.9	77
54	Range of Normal Liver Stiffness and Factors Associated WithÂlncreased Stiffness Measurements in Apparently HealthyÂlndividuals. Clinical Gastroenterology and Hepatology, 2019, 17, 54-64.e1.	2.4	59

#	Article	IF	CITATIONS
55	Recurrent or De Novo Allograft Steatosis and Long-term Outcomes After Liver Transplantation. Transplantation, 2019, 103, e14-e21.	0.5	77
56	Sofosbuvir and Ribavirin Eradication of Refractory Hepatitis E in an Immunosuppressed Kidney Transplant Recipient. Hepatology, 2019, 69, 2297-2299.	3.6	26
57	Differing Impact of Sarcopenia and Frailty in Nonalcoholic Steatohepatitis and Alcoholic Liver Disease. Liver Transplantation, 2019, 25, 14-24.	1.3	71
58	Gender, Race and Disease Etiology Predict De Novo Malignancy Risk After Liver Transplantation: Insights for Future Individualized Cancer Screening Guidance. Transplantation, 2019, 103, 91-100.	0.5	30
59	Longâ€ŧerm outcomes of patients undergoing simultaneous liver transplantation and sleeve gastrectomy. Hepatology, 2018, 68, 485-495.	3.6	95
60	Cirrhotic Cardiomyopathy After Transplantation: Neither the Transient Nor Innocent Bystander. Hepatology, 2018, 68, 2008-2015.	3.6	45
61	Reply. Hepatology, 2018, 68, 789-789.	3.6	0
62	Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis. Inflammatory Bowel Diseases, 2018, 24, 1074-1081.	0.9	27
63	Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in Young Adults in the United States. Journal of Clinical Gastroenterology, 2018, 52, 339-346.	1.1	96
64	Systematic review of acute pancreatitis associated with interferon-α or pegylated interferon-α: Possible or definitive causation?. Pancreatology, 2018, 18, 691-699.	0.5	20
65	Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment. Annals of Hepatology, 2018, 17, 815-821.	0.6	4
66	Hypothyroidism is associated with worse outcomes of hepatocellular carcinoma patients after liver transplantation. Cancer Medicine, 2018, 7, 5870-5878.	1.3	14
67	Impact of Allograft Steatosis on Cardiovascular Outcomes. Current Transplantation Reports, 2018, 5, 206-211.	0.9	0
68	New-Onset Diabetes and Preexisting Diabetes Are Associated With Comparable Reduction in Long-Term Survival After LiverÂTransplant: A Machine LearningÂApproach. Mayo Clinic Proceedings, 2018, 93, 1794-1802.	1.4	46
69	Low to Intermediate Dose Atropine Administration During Dobutamine Stress Echocardiography in the Pre-Liver Transplant Population. Progress in Transplantation, 2018, 28, 361-367.	0.4	1
70	Editorial: transplantation in the setting of acuteâ€onâ€chronic liver failure—calculating chances. Alimentary Pharmacology and Therapeutics, 2018, 48, 99-100.	1.9	1
71	Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder. Blood, 2018, 132, 2979-2979.	0.6	0
72	Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic. Hepatology, 2017, 65, 2100-2109.	3.6	105

#	Article	IF	CITATIONS
73	Frequency and prognosis of acute pancreatitis associated with fulminant or non-fulminant acute hepatitis A: A systematic review. Pancreatology, 2017, 17, 166-175.	0.5	56
74	Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data. American Journal of Gastroenterology, 2017, 112, 581-587.	0.2	178
75	Review article: maximising quality of life while aspiring for quantity of life in endâ€stage liver disease. Alimentary Pharmacology and Therapeutics, 2017, 46, 16-25.	1.9	24
76	Increasing Burden of Chronic Liver Disease Among Adolescents and Young Adults in the USA: A Silent Epidemic. Digestive Diseases and Sciences, 2017, 62, 1373-1380.	1.1	68
77	Low Utility of Noninvasive Fibrosis Scores in Young Adults with Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2017, 112, 652-653.	0.2	5
78	The Long Winding Road to Transplant: How Sarcopenia and Debility Impact Morbidity and Mortality on the Waitlist. Clinical Gastroenterology and Hepatology, 2017, 15, 1492-1497.	2.4	51
79	Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States. Clinical Gastroenterology and Hepatology, 2017, 15, 767-775.e3.	2.4	112
80	Fatty allograft and cardiovascular outcomes after liver transplantation. Liver Transplantation, 2017, 23, S76-S80.	1.3	11
81	Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation. Transplantation, 2017, 101, 2873-2882.	0.5	46
82	Sarcopenia in hiding: The risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis. Hepatology, 2017, 66, 2055-2065.	3.6	196
83	Charcoal hemoperfusion in the treatment of medically refractory pruritus in cholestatic liver disease. Hepatology International, 2017, 11, 384-389.	1.9	11
84	Liver transplantation after share 35: Impact on pretransplant and posttransplant costs and mortality. Liver Transplantation, 2017, 23, 11-18.	1.3	20
85	The reality of de novo malignancy: Sadly, not fake news. Liver Transplantation, 2017, 23, 1367-1368.	1.3	0
86	Systematic review of mixed cryoglobulinemia associated with hepatitis E virus infection: association or causation?. Gastroenterology Report, 2017, 5, 178-184.	0.6	49
87	Cryptogenic Cirrhosis and Sitosterolemia: A Treatable Disease If Identified but Fatal If Missed. Annals of Hepatology, 2017, 16, 970-978.	0.6	15
88	Systematic review with metaâ€analysis: the association between hepatitis E seroprevalence and haemodialysis. Alimentary Pharmacology and Therapeutics, 2017, 46, 790-799.	1.9	25
89	Nonalcoholic fatty liver. Current Opinion in Organ Transplantation, 2016, 21, 99-106.	0.8	20
90	The Intestinal Microbiome and the Liver Transplant Recipient. Transplantation, 2016, 100, 61-68.	0.5	42

#	Article	lF	CITATIONS
91	425 Underlying NASH and Recurrent or Denovo Allograft Steatosis Are Predictive of Long Term Cardiovascular Events in Liver Transplant Recipients. Gastroenterology, 2016, 150, S1033.	0.6	0
92	De Novo Malignancies After Transplantation. Medical Clinics of North America, 2016, 100, 551-567.	1.1	45
93	The evolving role of the microbiome in liver failure and liver transplantation. Liver Transplantation, 2016, 22, 58-61.	1.3	2
94	Su1440 Multicenter Study Evaluating Prevalence of Genotypic Resistance-Associated Variants of Hepatitis C Virus Genotype 1 in Ledipasvir/Sofosbuvir Relapsers. Gastroenterology, 2016, 150, S1100.	0.6	0
95	Comparing Cardiopulmonary Exercise Testing in End-Stage Liver Disease Patients. Transplantation Proceedings, 2015, 47, 2470-2472.	0.3	0
96	Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States. BMC Infectious Diseases, 2015, 15, 371.	1.3	31
97	Mammalian target of rapamycin inhibition after solid organ transplantation: <i>can</i> it, and <i>does</i> it, reduce cancer risk?. Clinical Transplantation, 2015, 29, 654-663.	0.8	10
98	Cardiovascular disease after liver transplantation: When, What, and Who Is at Risk. Liver Transplantation, 2015, 21, 889-896.	1.3	154
99	Intrapulmonary vascular dilatations are common in portopulmonary hypertension and may be associated with decreased survival. Liver Transplantation, 2015, 21, 1355-1364.	1.3	38
100	Impact of fibrosis progression on clinical outcome in patients treated for post―transplant hepatitis C recurrence. Liver International, 2015, 35, 2433-2441.	1.9	27
101	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology, 2015, 149, 649-659.	0.6	725
102	Bariatric Surgery in Patients With Cirrhosis With and Without Portal Hypertension: A Single-Center Experience. Mayo Clinic Proceedings, 2015, 90, 209-215.	1.4	59
103	Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology, 2015, 61, 1880-1886.	3.6	166
104	Outcomes in liver transplantation: Does sex matter?. Journal of Hepatology, 2015, 62, 946-955.	1.8	79
105	Is 40 the new 30?. Transplant International, 2015, 28, 146-147.	0.8	0
106	Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology, 2015, 62, 1004-1012.	3.6	54
107	Keys to long-term care of the liver transplant recipient. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 639-648.	8.2	44
108	HBIG Remains Significant in the Era of New Potent Nucleoside Analogues for Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. International Reviews of Immunology, 2014, 35, 1-13.	1.5	12

#	Article	IF	CITATIONS
109	Obesity evolution or revolution: There is more to it than meets the BMI. Liver Transplantation, 2014, 20, 253-254.	1.3	1
110	The impact of gender and <scp>NASH</scp> on chronic kidney disease before and after liver transplantation. Liver International, 2014, 34, 1259-1266.	1.9	49
111	Serum adipokine and inflammatory markers before and after liver transplantation in recipients with major cardiovascular events. Liver Transplantation, 2014, 20, 791-797.	1.3	20
112	Natural History of Recurrent Hepatitis C: Impact of Immunosuppression. , 2014, , 29-43.		0
113	Extrahepatic implications of metabolic syndrome. Liver Transplantation, 2013, 19, S56-S61.	1.3	2
114	Nutritional status of patients with alcoholic cirrhosis undergoing liver transplantation: time trends and impact on survival. Transplant International, 2013, 26, 788-794.	0.8	29
115	Interactions of allelic variance of PNPLA3 with nongenetic factors in predicting nonalcoholic steatohepatitis and nonhepatic complications of severe obesity. Obesity, 2013, 21, 1935-1941.	1.5	17
116	Investigation of PNPLA3 and IL28B Genotypes on Diabetes and Obesity After Liver Transplantation: Insight Into Mechanisms of Disease. American Journal of Transplantation, 2013, 13, 2450-2457.	2.6	46
117	Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: A case-control study and literature review. Liver Transplantation, 2013, 19, 1311-1317.	1.3	11
118	Nonalcoholic Steatohepatitis in Bariatric Patients with a Diagnosis of Obstructive Sleep Apnea. Obesity Facts, 2012, 5, 587-596.	1.6	13
119	The Course of Posttransplant Hepatitis C Infection. Transplantation, 2012, 94, 197-203.	0.5	46
120	Reducing the load: The evolution and management of obesity and nonalcoholic steatohepatitis before liver transplantation. Liver Transplantation, 2012, 18, S52-S58.	1.3	17
121	Burden of de novo malignancy in the liver transplant recipient. Liver Transplantation, 2012, 18, 1277-1289.	1.3	104
122	Long-term Medical Management of the Liver Transplant Recipient: What the Primary Care Physician Needs to Know. Mayo Clinic Proceedings, 2012, 87, 779-790.	1.4	54
123	Liver transplantation and nonalcoholic fatty liver disease. Clinical Liver Disease, 2012, 1, 131-133.	1.0	2
124	Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: An analysis of the Scientific Registry of Transplant Recipients Database. Liver Transplantation, 2012, 18, 1029-1036.	1.3	56
125	Risk for Immune-Mediated Graft Dysfunction in Liver Transplant Recipients With Recurrent HCV Infection Treated With Pegylated Interferon. Gastroenterology, 2012, 142, 1132-1139.e1.	0.6	104
126	Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation. Liver Transplantation, 2012, 18, 514-523.	1.3	27

#	Article	IF	CITATIONS
127	Growth hormone, dehydroepiandrosterone and adiponectin levels in nonâ€alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients. Liver International, 2012, 32, 279-286.	1.9	49
128	Recipient IL28B Polymorphism Is an Important Independent Predictor of Posttransplant Diabetes Mellitus in Liver Transplant Patients with Chronic Hepatitis C. American Journal of Transplantation, 2012, 12, 737-744.	2.6	26
129	Frequency and Outcomes of Liver Transplantation for Nonalcoholic Steatohepatitis in the United States. Gastroenterology, 2011, 141, 1249-1253.	0.6	1,006
130	NAFLD and Insulin Resistance Do Not Increase the Risk of Postoperative Complications Among Patients Undergoing Bariatric Surgery—A Prospective Analysis. Obesity Surgery, 2011, 21, 310-315.	1.1	31
131	Noninvasive diagnosis of acute cellular rejection in liver transplant recipients: A proteomic signature validated by enzyme-linked immunosorbent assay. Liver Transplantation, 2011, 17, 723-732.	1.3	48
132	Metabolic syndrome: Is immunosuppression to blame?. Liver Transplantation, 2011, 17, S38-S42.	1.3	64
133	Fatty Liver and Liver Transplantation. Clinics in Liver Disease, 2009, 13, 621-630.	1.0	36
134	Liver Transplantation for Hepatic Epithelioid Hemangioendothelioma: The Canadian Multicentre Experience. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 821-824.	1.8	42
135	Metabolic syndrome in liver transplant recipients: Prevalence and association with major vascular events. Liver Transplantation, 2007, 13, 1109-1114.	1.3	287
136	Retransplantation for hepatitis C: Results of a U.S. multicenter retransplant study. Liver Transplantation, 2007, 13, 1246-1253.	1.3	102